The present invention provides a novel compound having antagonism of P2X3 and/or P2X2/3 receptors.A pharmaceutical composition having antagonism of P2X3 and/or P2X2/3 receptors comprises the compound represented by formula (I):[in formula, cycle A is substituted or unsubstituted cycloalkane of 5~7 members, substituted or unsubstituted cycloalkene of 5~7 members； C is carbon atom； -X-is -N(R16)- and the like； R16 is hydrogen, substituted or unsubstituted alkyl and the like； R7 is substituted or unsubstituted heteroaryl of 5 or 6 members, or substituted or unsubstituted aryl of 6~10 members； Q1 and Q2 are each independently carbon atom or nitrogen atom； -L- is -O-, -S- and the like； R6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl and the like； R2 is hydrogen, hydroxyl and like]；or pharmaceutically acceptable salts or solvates thereof.本發明提供一種新穎之具有P2X3及/或P2X2/3受體拮抗作用的化合物。一種具有P2X3及/或P2X2/3受體拮抗作用之醫藥組成物，其含有式(I)所示之化合物：[式中，環A為經取代或非經取代之5~7員環烷、經取代或非經取代之5~7員環烯等；C為碳原子；-X-為-N(R16)-等；R16為氫、經取代或非經取代之烷基等；R7為經取代或非經取代之5員或6員雜芳基或經取代或非經取代之6~10員芳基；Q1及Q2各自獨立為碳原子或氮原子；-L-為-O-、-S-等；R6為經取代或非經取代之環烷基、經取代或非經取代之環烯基等；R2為氫、羥基等]；或其製藥上可容許的鹽或彼等之溶劑合物。
